Fig. 1
Nociceptive effect of VEGFRs selective ligands infused in spinal cord. The pain threshold was measured by the Cold plate test over time after the i.t. injection of the different molecules. Effect of (a) VEGF165b (n = 7), (b) the VEGFR-1 selective agonist PlGF-2 (n = 5), (c) the VEGFR-2 selective agonist VEGF-E (n = 5), (d) the selective anti-VEGFR-1 antibody D16F7 (n = 7) or a murine control IgG (n = 5) and (e) the selective anti-VEGFR-2 antibody DC101 (n = 5). (f) Effect of DC101 in mice pre-treated (15 min before) with D16F7. Each value represents the mean ± SEM. *P < 0.05 and **P < 0.01 vs vehicle-treated animals; °°P < 0.01 vs DC101 6 ng treated animals. The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison